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CHAPTER I
INTRODUCTION
I.1 Overview of Molecular Imaging
 Since the discovery of X-Rays by Wilhelm Conrad Röntgen in 1895, medical 
imaging has  become a powerful clinical tool in the diagnosis and treatment of disease. 
Planar X-Ray, Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and 
ultrasound imaging have become ubiquitous in the clinical setting. However, these 
modalities have until recently been limited to use as anatomical imaging modalities, i.e. 
imaging of structure rather than biological function. Molecular imaging, “the 
visualization, characterization and measurement of biological processes at the 
molecular and cellular levels in humans and other living systems” (1)  has recently 
emerged as a clinical and research tool to interrogate functional biological processes. 
Molecular imaging can be utilized in the detection, diagnosis and prognosis of disease 
as well as to aid in the determination of treatment response.
 The most important component of molecular imaging is  the molecular imaging 
agent itself which is  composed of two basic parts, the targeting moiety and the signaling 
moiety (2). The targeting moiety directs the probe to the biological target of interest. A 
number of types of targeting moieties are currently in use including antibodies, proteins, 
peptides, and small molecules.  The signaling moiety provides  a means for detection of 
the molecular imaging probe by an imaging system. Signaling moieties include 
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radionuclides, fluorophores, hyperpolarized molecules, nanoparticles, microbubbles and 
even endogenous substances. 
 The ability to label a targeting moiety with many types of signaling moieties 
allows molecular imaging to occur across  a number of imaging modalities (3). The most 
common clinical molecular imaging modalities are Positron Emission Tomography (PET) 
and Single Photon Emitted Computer Tomography (SPECT), which utilize radionuclides 
as signaling moieties. PET imaging with positron emitting radionuclides such as  11C, 18F, 
64Cu, and 68Ga allows imaging resolutions on the order of millimeters with very high 
sensitivity in both clinical and preclinical settings. SPECT imaging utilizes radionuclides 
that exhibit a single photon decay including 99mTc, 123I, 111In, and 177Lu. SPECT has 
somewhat lower sensitivity compared to PET and has lower resolution in the clinical 
setting, but can have higher resolution in pre-clinical imaging due to specialized 
hardware for small animal imaging. Fluorescence imaging with fluorescent dyes, 
proteins, or quantum dots can have both high sensitivity and resolution when not 
obscured by overlying tissues. However, it can quickly lose both when tissue is present 
between the fluorophore and the detector due to scattering and absorbance of the 
incident and fluorescent photons, as  well as the presence of autofluorescence in the 
tissue. In practice, fluorescence imaging is mainly limited to pre-clinical imaging due to 
depth of detection issues. However fluorescence can be effectively utilized in superficial 
or topical applications in humans. Bioluminescent imaging (BLI), a purely preclinical 
imaging modality, utilizes reporter genes typically expressing luciferase, which cleaves 
injected luciferin leading to the release of light. BLI can have very high sensitivity due to 
the lack of naturally occurring light sources, but has roughly millimeter resolution due to 
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scattering and absorbance of light while traveling though tissue. MRI, while typically 
used for anatomical imaging, may be used as a molecular imaging modality. Signaling 
moieties containing metals that effect either the T1 or T2 relaxation times of hydrogen 
such as Gadolinium or superparamagnetic iron oxide particles, or imaging 19F rather 
than hydrogen have been developed. However, each exhibit very low sensitivity 
compared to PET. Additionally, Magnetic Resonance Spectroscopy (MRS) may be 
utilized to assay naturally occurring molecules or to detect exogenous molecules that 
induce chemical shift, however MRS is very low sensitivity with low resolution compared 
to MRI. Finally, ultrasound imaging can be used as a molecular imaging modality by the 
use of targeted microbubbles. Tiny gas-containing bubbles on the order of microns in 
diameter are injected into the blood stream and can hone to various intravascular 
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Modality Signal Clinical Sensitivity* ResolutionClinical; Pre-Clinical
PET 11C, 18F, 64Cu, 68Ga Yes 1 ~4 mm; ~2 mm
SPECT 99mTc, 123I, 111In, 177Lu Yes 10-1-10-2 6-8 mm; 1-2 mm
Fluorescence
Fluorescent proteins, 
fluorochromes, 
quantum dots
Potential 10-2-1† N/A; 1-3 mm
BLI Light No 1-102 † N/A; 1-10 mm
MRI Gadolinium, SPIO, USPIO, 19F Potential 10
-5 1 mm; 80-100 µm
MRS
Endogenous 
compounds, 
hyperpolarized 13C
Yes < 10-5 ~1mm; < 1mm
Ultrasound Microbubbles Potential > 10-5 300-500 µm; 50 µm
* Relative to PET, † Depth-dependent
 Adapted from (2, 3)
targets. Real time imaging ability makes ultrasound attractive for molecular imaging. 
However, as  well as relatively high resolution in pre-clinical settings, however the 
sensitivity is  low compared to PET, limited to intravascular targets, and has not been 
extensively studied as a molecular imaging modality in a clinical setting. A comparison 
of the performance and characteristics of these imaging modalities  can be found in 
Table 1.
 
I.2 Basics of PET imaging
 PET has become a powerful clinical and research tool in oncology, 
neurosciences, cardiology, and pharmacology in both small animals  and humans. PET 
detects  paired gamma rays that are produced following the positron emission decay of a 
radionuclide tracer. The 511 keV gamma rays are emitted at almost 180º and are 
detected by a ring of scintillators. Detection of two scintillation events within a short time 
window on opposite sides of the detector ring defines a line of response within which 
the positron annihilation is assumed to have taken place. Based upon the detection of 
millions of annihilation events, an image of the radiotracer distribution can be 
reconstructed via a number of algorithms. 
 Compared to many other in vivo imaging modalities, PET has the distinct 
advantage of being inherently quantitative. After calibration, the radioactivity in each 
voxel can be determined using a number of well-established methods. While inspection 
of PET images can be used for simple detection of tumors, especially clinically, it is 
difficult to make comparisons across subjects due to differences in windowing of the 
images, injected dose, and various physiological factors.  Study design for PET 
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generally breaks  down in to two categories, static methods and kinetic methods. In 
static PET imaging, the radiotracer is injected into the patient or animal, allowed to 
circulate, and imaged after the tracer has reached steady state in the tissue of interest. 
Typically, quantification is normalized to the injected activity and the weight of the 
patient, and is expressed as either percent injected dose per gram (%ID/g) or as 
standardized uptake value (SUV). In dynamic imaging, the radiotracer is infused into the 
subject while in the scanner and the uptake of the tracer can be followed until it reaches 
a steady state level. Time-activity curves are then generated for each tissue of interest 
and applied either to compartment modeling or graphical analysis  to determine a wide 
array of biologically relevant parameters. Typically, due to longer imaging times and the 
need to collect blood samples, dynamic imaging is typically utilized only in research 
studies requiring absolute quantification.
I.3 2-deoxy-2-(18F)fluoro-D-glucose (18FDG)
 18FDG is the only clinically approved PET tracer currently available for routine 
cancer detection and diagnosis. Essentially, a glucose molecule labeled with 18F at the 
2’ position instead of a normal hydroxyl group (4), 18FDG enters a cell via the same 
biochemical mechanisms as glucose through specialized glucose transporters, which 
are commonly elevated in cancer cells. However, once entering the cell 18FDG, like 
glucose, is phosphorylated by hexokinase and is  trapped in the cell. However, 18FDG 
cannot proceed with further glycolysis, due to the functionalization with 18F at the 2’ 
position. Image contrast arrises due to the increased glucose metabolism in neoplastic 
tissue compared to normal tissue and the resulting differential accumulation of trapped 
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probe. Imaging with 18FDG exhibits some drawbacks such as  elevated uptake in 
inflammation as well as non-neoplastic tissues of high glucose metabolism including the 
heart, muscles and brain. Additionally, the cellular glycolysis pathway is a complicated 
biological process that can have non-intuitive effects on 18FDG uptake, especially in an 
anti-cancer treatment setting. One must be aware of these effects when interpreting 
18FDG-PET imaging.
I.4 Summary
 While molecular imaging is a rapidly emerging tool in the clinic, by far the most 
common modality and molecular probe are PET and 18FDG, respectively. The work 
contained herein describes the application of 18FDG-PET imaging to a preclinical mouse 
model of human lung cancer. While other modalities could have been used for this 
study, 18FDG-PET imaging was chosen so as to expedite the translation of from pre-
clinical imaging to human imaging. 
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CHAPTER II
18FDG-PET PREDICTS PHARMACODYNAMIC RESPONSE TO OSI-906, A DUAL 
IGF-1R/IR INHIBITOR IN PRECLINICAL MOUSE MODELS OF LUNG CANCER
II.1 Abstract 
Purpose: To evaluate 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography 
imaging (18FDG-PET) as a predictive, non-invasive, pharmacodynamic (PD) biomarker 
of response following administration of a small-molecule IGF-1R/IR inhibitor, OSI-906.
Experimental Design: In vitro uptake studies of 3H-2-deoxy glucose following OSI-906 
exposure were performed evaluating correlation of dose with inhibition of IGF-1R/IR as 
well as markers of downstream pathways and glucose metabolism. Similarly, in vivo PD 
effects were evaluated in human tumor cell line xenografts propagated in athymic nude 
mice by 18FDG-PET at 2, 4, and 24 hours following a single treatment of OSI-906 for the 
correlation of  inhibition of receptor targets and downstream markers. 
Results: Uptake of 3H-2-deoxy glucose and 18FDG was significantly diminished 
following OSI-906 exposure in sensitive tumor cells  and subcutaneous xenografts  (NCI-
H292) but not in an insensitive model lacking IGF-1R expression (NCI-H441). 
Diminished pharmacodynamic 18FDG-PET collected immediately following the initial 
treatment agreed with inhibition of pIGF-1R/pIR, reduced PI3K and MAPK pathway 
activity, and predicted tumor growth arrest as measured by high-resolution ultrasound 
imaging. 
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Conclusion: 18FDG-PET appears to serve as a rapid, non-invasive, PD marker of 
IGF-1R/IR inhibition following a single dose of OSI-906 and should be explored clinically 
as a predictive clinical biomarker in patients undergoing IGF-1R/IR-directed cancer 
therapy. 
II.2 Introduction 
The insulin-like growth factor-1 receptor (IGF-1R) is a tetrameric transmembrane 
receptor tyrosine kinase that is widely expressed in normal human tissues and is  up-
regulated in a number of human cancers including colorectal, non-small cell lung, 
ovarian and pediatric cancers. The receptor is composed of two α and two β subunits 
linked by disulfide bonds  in which the extracellular α subunit is  responsible for ligand 
binding and the β subunit consists of a transmembrane domain and a cytoplasmic 
tyrosine kinase domain. Ligand binding activates the tyrosine kinase activity of IGF-1R 
and results  in trans-β subunit autophosphorylation and stimulation of signaling cascades 
that include PI3K-mTOR and MAPK pathways. Activation of IGF-1R has been reported 
to stimulate proliferation, survival, transformation, metastasis  and angiogenesis, 
whereas inhibition of IGF-1R has been shown to impede tumorigenesis  in several 
human xenograft models (5). 
Increased expression of IGF-1R and its  cognate ligands, IGF-I and IGF-II has 
been demonstrated in a wide range of solid tumors and hematologic neoplasias  relative 
to normal tissue levels. Epidemiologic studies have shown an increased risk for the 
development of colon, lung, breast and bladder cancers with increased circulating levels 
of IGF-I (6-9). Additionally, IGF-1R expression levels have been correlated to poor 
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prognosis in renal cell carcinoma(10, 11). IGF-1R signaling mechanism has also been 
linked to resistance to various anti-tumor therapies including epidermal growth factor 
receptor inhibitors (5, 10, 12, 13).
Similarly, the insulin receptor (IR) is composed of a heterotetramer consisting of 
two extracellular α -subunits and two transmembrane β -subunits. Binding of insulin to 
the IR extracellular α-subunit causes a conformational change bringing together the two 
β-subunits. Activated IR tyrosine kinase phosphorylates  several intracellular substrates 
including IRS-1-4, Shc, Gab1 and Cbl. These phosphorylated proteins  provide a 
docking site for effector proteins  containing Src homology 2 (SH2) domains further 
linking IR to PI3-kinase (PI3K) via the regulatory p85 subunit. Homology between IR 
and IGF-IR ranges from 45-65% in the ligand binding domains to 60-85% in tyrosine 
kinase domains. Expression of IR is highest in adipose tissue and to a lesser extent in 
liver, heart and muscle (14). Overexpression of IR in breast, colon, lung, ovarian and 
thyroid cancers suggest a role of IR in tumor progression (14). More recently it has been 
shown that forced overexpression of IR is tumorigenic in mice (15). 
OSI-906 is a potent and highly selective tyrosine kinase inhibitor that exhibits 
similar biochemical potency against IGF-1R (8 nM) and IR (14 nM) and is  greater than 4 
orders of magnitude more selective for IGF-1R/IR compared to a wide number of other 
receptor and non-receptor kinases (16). Within a panel of >180 kinases only IGF-1R 
and IR were inhibited by greater than 50% at 1.0 µM OSI-906. Inhibition of cell 
proliferation and induction of apoptosis following exposure to OSI-906 appears to be 
directly linked to inhibition of AKT in colorectal, lung, and pancreatic cancer cell lines (5, 
16). In addition, OSI-906 has shown potent antitumor activity in vivo in several xenograft 
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models  (5). Since IGF-1R and IR pathway signaling is linked to glucose metabolism, we 
asked whether 18FDG-PET could function as a surrogate pharmacodynamic marker for 
OSI-906. To this end, we employed in vitro cell culture assays and in vivo animal 
models  measuring uptake of radioactive glucose analogues as a function of treatment 
by OSI-906. Our data demonstrate that glucose uptake is rapidly inhibited in vitro and in 
vivo and tracks  with IGF-1R, IR and AKT inhibition after OSI-906 treatment in sensitive 
tumors. Moreover, reduced glucose uptake was readily observed after OSI-906 
treatment in tumor tissues using 18FDG-PET imaging methodologies. Hence, 18FDG-
PET may function as  a rapid, non-invasive tumor specific pharmacodynamic (PD) 
marker for OSI-906 in the clinical setting where accurate assessment of PD effects  is 
often times limited by the lack of readily accessible tumor samples. As such 18FDG-PET 
may be a useful clinical tool in identifying active doses and patients potentially sensitive 
to this novel antitumor agent warranting further clinical investigation of this approach.
II.3 Materials and Methods
II.3.1 Immortal Human Lung Cancer Cell Lines 
 Human non-small cell lung carcinoma cell lines (NCI-H292, NCI-H441) were 
obtained from American Type Culture Collection (Manassas, VA). All cell lines were 
maintained in RPMI 1640 media (Mediatech, Manassas, VA) supplemented with 10% 
FBS (Sigma, St. Louis, MO) and 1% sodium pyruvate (Mediatech, Manassas, VA) and 
maintained at 37°C and 5.0% CO2. Cells were propagated to 80-90% confluency prior 
to in vitro and in vivo assays. 
II.3.2 3H-2-Deoxy Glucose In Vitro Uptake Assay
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 Cells  were seeded in 12-well tissue culture plates (Becton Dickinson, Franklin 
Lakes, NJ) at a density of 9.0 x 105 cells  per well in normal glucose (11.1 mM) media 
and allowed to attach for 6-8 hours at 37°C (n = 3 wells/group). The media was then 
changed to 5.5 mM glucose media and the cells  were allowed to equilibrate overnight. 
Three hours prior to the assay, the media was again removed and replaced with media 
containing 0.0 mM glucose (glucose starvation). The cells  were then treated with 
varying concentrations of OSI-906 (0.0 µM to 30 µM) and 0.15 mCi of 3H-2-deoxy 
glucose (Perkin Elmer, Boston, MA). After 30 minutes the media was removed, the cells 
placed on ice and washed once with ice cold PBS (Mediatech, Manassas, VA). The 
PBS was then removed and the cells were lysed in RIPA buffer (Sigma, St. Louis, MO) 
for 15 minutes on ice. The lysates were harvested and counted in a Beckman LS6500 
Liquid Scintillation counter (Fullerton, CA). 3H-2-deoxy glucose uptake was calculated 
as raw counts and normalized to control samples (0.0 µM OSI-906). As a positive 
control of glucose uptake inhibition, NCI-H292 cells  were treated with increasing 
concentrations (2.5 µM – 10 µM) of cytochalasin B (Sigma, St. Louis, MO), a known 
inhibitor of GLUT1 and GLUT4 glucose transporters.  
II.3.4 Mouse Models
 Studies  involving mice were conducted in accordance with federal and 
institutional guidelines. NCI-H292 and NCI-H441 non-small cell human xenograft tumors 
were generated as  described (17). Briefly, 4 x 106 cells were injected subcutaneously on 
the right flank of 5-6 week old female athymic nude mice (Charles Rivers, Wilmington, 
MA). Using this method, palpable tumors were typically observed within 2 weeks 
following injection of cells and were allowed to progress until approximately 150-200 
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mm3, and then randomized for treatment studies. Measurement of volume was 
performed using high resolution ultrasound imaging as  described (18). Mice were 
treated when the tumors reached ~200 mm3 in volume. Blood glucose was measured 
using a Freestyle digital glucose meter and test strips  (Abbott) before and at 2, and 4 
hours after treatment with 60 mg/kg OSI-906 or 25 mM tartaric acid vehicle.
II.3.5 Procurement of 18FDG
 18FDG was synthesized in the Vanderbilt University Medical Center 
Radiopharmacy and distributed by PETNET. The average radiochemical purity of the 
product was 98.5% and specific activity was >1,000 Ci/mmol.
II.3.6 18FDG-PET Imaging
 Animal handling methods in preparation for and during 18FDG-PET imaging were 
similar to published protocols (19-21). Briefly, prior to imaging, mice were fasted 
overnight and allowed to acclimate to the PET imaging facility environment for at least 1 
hour while in a warmed chamber at 31.5 0C. Mice were administered a single dose of 
OSI-906 at 60 mg/kg in a 25 mM tartaric acid vehicle via oral gavage (n=8/group). 
18FDG was administered via a single retro orbital injection of ~200 µCi (100 µL) and 
imaged 2, 4 and 24 hours post dosing of OSI-906, or 4 hours after tartaric acid vehicle. 
Mice were conscious during the uptake period and maintained in a warmed chamber. 
Following a 50-minute uptake period, 10-minute static PET scans were collected on a 
Concorde Microsystems micro-PET Focus 220 (Siemens, Culver City, CA). Mice were 
maintained under 2% isofluorane anesthesia in 100% O2 at 2 L/min and kept warm via a 
circulating water heating for the duration of the scan. Immediately following imaging, 
mice were sacrificed and tissues collected for molecular analysis. PET images were 
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reconstructed using the ordered subsets expectation maximization (OSEM) algorithm. 
The percent injected-dose per gram of tissue (%ID/g) was calculated from analysis of 
tumor regions of interest using ASIPro software (Concorde Microsystems Inc.). 
II.3.7 Statistical Analysis
 Wilcoxon Rank Sum tests were performed to compare each treatment time point 
to vehicle treated mice. Comparisons were unadjusted for the multiplicity of testing and 
were deemed significant if p < 0.05. 
II.3.8 Pharmacokinetic Analysis
 At 2, 4, and 24 hours after administration of OSI-906 blood was collected via 
cardiac puncture and placed in BD Microtainer EDTA collection tubes (Becton 
Dickinson, Franklin Lakes, NJ). The samples were centrifuged at 1500 x g for 10 
minutes and plasma protein precipitated with methanol. Analysis  of drug concentration 
was performed by HPLC-MS tandem mass spectroscopy (Applied Biosystems, Foster 
City, CA).  
II.3.9 Western Blot Analysis
 Phosphorylation of IGF-1R and IR in cells and tumor samples were analyzed by 
immunoprecipitation/Western blotting. Cells were lysed using NP-40 lysis buffer (Sigma, 
St. Louis, MO). Tumor samples were homogenized using Precellys 24 (MO BIO 
Laboratories Inc., Carlsbad, CA) in tumor lysis buffer (1% Triton X-100, 10% glycerol, 50 
mM HEPES (pH 7.4), 150 mM NaCl, 1.5 mM MgCl2, 1 mM EDTA supplemented with 
fresh protease inhibitor cocktail (Sigma, St. Louis, MO), phosphatase inhibitor cocktail 
(Sigma, St. Louis, MO), 10 mM NaF and 1 mM sodium orthovanadate). After pre-
clearing by centrifugation (14,000 rpm for 15 minutes), 1 mg of total protein was 
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immunoprecipitated with anti-phosphotyrosine antibody (pY20, Exalpha, Shirley, MA) at 
4 0C overnight. The immunoprecipitates were separated on SDS-PAGE and 
immunoblotted with a total IGF-1R antibody (Cell Signaling, Danvers, MA) followed by 
detection using enhanced chemiluminesence (GE Healthcare Life Sciences, 
Piscataway, NJ). The blots were re-probed with total IR antibody (Cell Signaling, 
Danvers, MA). Phosphorylated IGF1-R and IR bands were quantified using an Image 
Quant LAS 4000 with Image Quant TL 7.0 software (GE Healthcare Life Sciences, 
Piscataway, NJ).
Markers of altered glycolysis  were analyzed by Western blot analysis. Tumor or 
cell lysate samples were separated on SDS-PAGE, immunoblotted and detected using 
enhanced chemiluminesence (GE Healthcare Life Sciences, Piscataway, NJ). The 
antibodies included pAKT (Ser473), total AKT, pS6 (Ser235/236), pERK 1/2, total ERK 
1/2, (Cell Signaling, Danvers, MA) and β-actin (Sigma, St. Louis, MO). The 
phosphorylated to total signal intensities were quantified as above.
II.3.10 RTK Analysis
 Tumor lysates were prepared according to manufactures protocol (Proteome 
Profiler, R&D Systems, Minneapolis, MN) in NP-40 lysis buffer and clarified by 
centrifugation. The samples were incubated with the Human Phospho-RTK Array at 
2000 µg total protein overnight at 4 0C with rocking. The arrays were developed using 
Super- Signal FEMTO ECL detection (Pierce, Rockford, IL). The phospho-spots  on the 
RTK blot were quantified using Image Quant LAS 4000 with Image Quant TL 7.0 
software (GE Healthcare Life Sciences, Piscataway, NJ)
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II.4 Results
II.4.1 Sensitivity of Xenograft Models to OSI-906
 Non-small cell lung cancer is a potentially attractive indication for OSI-906 due to 
the implication of IGF1R/IR as a driver in this, as well as drug resistance in this setting. 
We established sensitivity of the NCI-H292 and NCI-H441 xenograft models to OSI-906 
in vivo by measuring tumor volumes longitudinally with high resolution ultrasound 
imaging. Daily treatment with 60 mg/kg OSI-906 over 10 days resulted in tumor growth 
inhibition in the NCI-H292 xenografts compared to controls  (Fig. 1A), but no growth 
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F Fig. 1 Validation of cell lines. Daily treatment of mice bearing NCI-H292 xenografts 
with 60 mg/kg OSI-906 results  in significant tumor growth inhibition (A) compared to 
analogously treated vehicle controls. In contrast, NCI-H441 xenografts (B) do not exhibit 
a difference in tumor growth when comparing OSI-906-treated and vehicle-treated 
cohorts. Receptor tyrosine kinase (RTK) arrays (C), illustrate that NCI-H292 cells 
possess relatively high levels  of pIGF-1R and pIR compared to the barely detectable 
levels of pIGF-1R and pIR in NCI-H441 cells.
changes were observed in the non-responsive NCI-H441 xenografts (Fig. 1B). We 
found that NCI-H292 tumors had considerably higher levels  of pIGF-1R and pIR than 
NCI-H441 tumors (Fig. 1C).
II.4.2 Inhibition of 3H-2-Deoxy glucose uptake in vitro
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Fig. 2. In vitro treatment response. 3H-2-deoxy glucose uptake 30 minutes after 
OSI-906 treatment in NCI-H292 cells showed a dose-dependent decrease (A). Similar 
decreases in 3H-2-deoxy glucose uptake were seen at higher doses of OSI-906 in the 
non responding NCI-H441 cells compared with the responding NCI-H292 cells (B). 
Treatment with cytochalasin B as a positive control in NCI-H292 cells  demonstrated 
that 3H-2-deoxy glucose uptake is directly affected by exposure OSI-906, and can be 
linked directly to cellular pathways associated with glucose metabolism (C). Western 
blot of NCI-H292 cells following 30 minutes of exposure to OSI-906 shows target 
inhibition of pIGF-1R and pIR at all doses as well as inhibition of downstream targets 
pAKT and pS6 (D).
 We assessed the effect of OSI-906 treatment on uptake of 3H-2-deoxy glucose in 
NCI-H292 and NCI-H441 cells in vitro. Cells were treated for only 30 minutes  with 
OSI-906 in order to avoid potential anti-proliferative effects of the drug to interfere with 
this  endpoint analysis. OSI-906 treatment resulted in a rapid and dose dependent 
inhibition of uptake of the radiotracer in the NCI-H292 cell line (Fig. 2A). The percent 
inhibition ranged from 12% to 60% as the dose increased from 1.0 µM to 30 µM 
OSI-906. In comparison the NCI-H441 cell line demonstrated a reduced sensitivity to 
OSI-906. For the NCI-H292 cell line a 35% decrease in uptake of 3H-2-deoxy glucose 
was achieved at 10 µM OSI-906 whereas in the NCI-H441 cell line the same decrease 
of the radiotracer was observed at only 30 µM OSI-906 (Fig. 2B). Analysis for cell death 
by FACS using the Invitrogen Live/Dead assay determined no significant cell death at all 
OSI-906 concentrations (1.0 µM -30 µM) tested compared to 0.05% DMSO controls 
(data not shown). As a positive control, cytochalasin B (2.5 µM-10 µM) was 
administered to the NCI-H292 cells  and evaluated for 3H-2-deoxy glucose uptake in an 
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Fig. 3. In Vitro treatment time course. Western blot of NCI-H292 cells treated with 
10nM, 100 nM, 500 nM, 1 µM, and 5 µM OSI-906 show target inhibition over a 24 hour 
time course. All concentrations of OSI-906 induce a reduction in pIGF-1R at 2 hours, and 
inhibition remains through 24 hours in all but the lowest, 10 nM concentration.
analogous manner. Figure 2C shows that cytochalasin B significantly inhibits  uptake of 
the radiotracer by 85-90% in this cell line, and that the inhibition of 3H-2-deoxy glucose 
by OSI-906 in NCI-H292 cells represents a rapid PD effect.
II.4.3 Correlation with target-pathway inhibition in vitro
 NCI-H292 cell lysates were treated with an increasing concentration of OSI-906 
(0.0 µM-10 µM) for 30 minutes  and then analyzed for pIGF-1R, pIR, pERK 1/2, pAKT, 
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Fig. 4. In vivo 18FDG-PET. Representative transverse 18FDG-PET images of NCI-H292 
and NCI-H441 tumor xenografts (A) show that 18FDG uptake is  significantly reduced (p 
<0.05) in the NCI-H292 xenografts  at all time points following a single treatment of 60 
mg/kg OSI-906 (B) while NCI-H441 xenografts show no changes in 18FDG uptake (C).
pS6 and β-actin as shown in Figure 2D. We observed a significant decrease in 
phosphorylation of AKT and S6 suggesting a correlation between decreased glucose 
uptake and inhibition of targets downstream of IGF-1R and IR. NCI-H292 cells treated 
at lower concentrations (10 nm – 5 µM) over 2, 12 and 24 hours, demonstrated target 
inhibition at all concentrations at 2 hours, and sustained inhibition of pIGF-1R at both 12 
and 24 hours for all concentrations except 10 nM (Fig. 3). 
II.4.4 Inhibition of 18FDG uptake in vivo
 18FDG-PET images of mice bearing the NCI-H292 and NCI-H441 xenografts  are 
shown in Figure 4A. The NCI-H292 xenografts  (sensitive to OSI-906 treatment) show a 
significant decrease (p<0.05) in 18FDG uptake at 2, 4 and 24 hours post dosing with 
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Fig. 5. In vivo biological validation. RTK array analysis  demonstrates strong target 
inhibition of both pIGF-1R and pIR in NCI-H292 tumor lysates  at 2, 4 and 24 hours  after 
a single 60mg/kg treatment of OSI-906 (A,B). In vivo Western blot of NCI-H292 tumor 
lysates at 4 and 24 hours shows inhibition of selected markers of altered glycolysis, 
pERK 1/2, pAKT and pS6 at 4 hours post-dose that return to baseline levels by 24 
hours (C). 
OSI-906 compared to vehicle treated controls. NCI-H441 xenografts  (insensitive to 
OSI-906 treatment) did not demonstrate a significant change in uptake of 18FDG at any 
time point evaluated. Graphically, these results are shown in Figures 4B and 4C. The 
decreased %ID/g in the NCI-H292 xenografts is suggestive of a rapid PD effect 
observed by 18FDG imaging mediated by the inhibition of IGF-1R and IR pathways by 
OSI-906. Conversely, for the NCI-H441 xenograft model no difference in uptake of the 
radiotracer was observed in the tumor samples  between vehicle controls and the 
OSI-906 treatment group. 
II.4.5 Correlation with target pathway inhibition
 Target inhibition of both pIGF-1R and pIR by a single dose of OSI-906 at 60 mg/
kg in vivo in NCI-H292 xenograft tumors  is  shown in Fig. 5A. The data show that at 2 
and 4 hours post treatment target inhibition of pIGF-1R is  > 80% with 30% inhibition 
observed at 24 hours (Fig. 5B). The effect on pIR is equally pronounced, demonstrating 
significant target inhibition of this receptor. Target inhibition of pIR was > 80% at 4 hours 
post treatment with 40% inhibition observed at 24 hours. Inhibition of both target 
receptors correlated with decreased uptake of 18FDG in the same tumor samples 
20
Fig. 6. In vivo Western blot analysis. In vivo Western blot analysis of OSI-906 treated 
NCI-H441 tumors at 2, 4 and 24 hours shows no significant effect on pAKT levels 
compared to vehicle treated controls.
analyzed. Figure 5C shows the results  of 
a Western blot from tumor lysates  at 
selected time points  from mice bearing 
the NCI-H292 xenografts that were 
treated with 60mg/kg OSI-906 (n = 4/
group). We found reduced activation 
levels  of targets involved in glycolysis 
that are downstream of IGF-1R and IR, 
including pAKT, pS6 and pERK 1/2 as measured four hours post treatment with 
OSI-906 compared to untreated control lysates. Importantly, Western blot analysis  of 
OSI-906 treated NCI-H441 tumor xenografts  which do express very low levels of the 
target receptor showed no reduction in pAKT levels  at any time point compared to 
control (Fig. 6).
II.4.6 Pharmacokinetic Analysis
 Table 2 shows the drug concentration in the plasma samples from the NCI-H292 
xenografts remained at a constant concentration ~20 µM for 2 to 8 hours post dosing. 
By 24 hours post-dosing, the level of OSI-906 in the plasma had decreased by ~60% to 
approximately 6.5 µM, resulting in some potential loss of target coverage with time. 
II.5 Discussion
Catabolism of glucose through the TCA cycle in normal cells  is the preferred 
method of ATP production leading to cell proliferation and survival. It is now well known 
that many cancer cells  avidly consume glucose and produce lactic acid for ATP 
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Time Plasma Concentration (μM)
2 Hr 21.48
4 Hr 19.58
8 Hr 17.49
24 hr 6.52
Table 2. Pharmacodynamic analysis of 
OSI-906 in blood plasma. Plasma 
concentrations of OSI-906 in mice at 2, 4, 8 
and 24 hours following a single 60 mg/kg 
dose.
production despite the inefficiency of this  metabolic pathway. The reason why cancer 
cells utilize a less efficient means of ATP production remains elusive; however, recent 
studies suggest that in cancer cells  an increase in glycolysis, in addition to respiration, 
can generate energy more quickly than normal cells that rely on respiration alone. As a 
result, this high rate of glucose metabolism by cancer cells  has resulted in the wide use 
of 18FDG PET to image and diagnose rapidly dividing cells including tumors (22).
Both IGF-1R and IR signal through the PI3K signaling pathway. PI3K is linked to 
both growth control and glucose metabolism. PI3K directly regulates glucose uptake 
and metabolism via AKT mediated regulation of glucose transporter activation and 
expression (GLUT1 and GLUT4), enhanced glucose capture by increased hexokinase 
activity and stimulation of phosphofructokinase activity (23-26). PI3K activation thus 
renders cells  dependent on glucose leading to glucose addiction. In normal cells, 
activation of PI3K/AKT is highly controlled by dephosphorylation of phosphatidylinositol 
by PTEN. However, in many cancers, PTEN is  lost leading to constitutive activation of 
the PI3K pathway (27). Moreover, activation of this pathway can be enhanced by other 
mechanisms which, when combined, can constitute some of the more prevalent classes 
of mutations in human malignancy (e.g. PI3CA, AKT2, BCR-ABL, HER2/neu, etc.). 
Therefore, activation of AKT is likely the most important signaling event in relation to 
cellular metabolism, because AKT is sufficient to drive glycolysis and lactate formation 
and suppress macromolecular degradation in cancer (27, 28). It has been shown that 
various therapeutic agents  that disrupt the PI3K/AKT pathway, either directly or 
upstream of PI3K/AKT lead to decreased glucose uptake in tumors as measured by 
18FDG-PET (29). Furthermore, the ability to inhibit FDG uptake in tumors has been 
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shown to correlate well with treatment response in a number of cancers. As a 
consequence, 18FDG-PET has been used clinically in cancer patients  to predict 
response to various  therapies via the ability of agents to disrupt glucose metabolism 
and glucose uptake in tumors (26, 30-32).
  The primary purpose of these studies was to determine if 18FDG-PET could be 
used as an early, non-invasive PD biomarker for the dual kinase inhibitor OSI-906. We 
first determined in vitro using the sensitive cell line, NCI-H292 that a rapid decrease in 
3H-2-deoxy glucose uptake was observed in a dose dependent manner after treatment 
with pharmacologically relevant concentrations of OSI-906. In the NCI-H441 cell line 
reduced sensitivity to equimolar concentrations of OSI-906 was observed for the same 
assay. NCI-H292 cell lysates were then probed for markers of altered glycolysis by 
Western blot analysis and showed a significant reduction in pIGF-1R, pIR, pAKT, pS6, 
and pERK 1/2. Target inhibition of these markers strongly link IGF-1R and IR to the PI3 
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Fig. 7. Blood glucose measurements. Blood glucose levels increased at 2 and 4 
hours after OSI-906 administration, although levels did not reach statistical significance 
(p > 0.05), compared to baseline. No changes in blood glucose levels were seen in 
vehicle treated mice over a similar period (A). OSI-906 had no detectable effect on 
18FDG uptake in skeletal muscle (B). 18FDG uptake in liver was increased at 2 and 4 
hours after 60 mg/kg OSI-906 treatment but returned to baseline after 24 hours (C).
kinase and AKT pathways  and resultant changes in metabolic activity of cultured cells 
when exposed to OSI-906. 
  In vivo, decreased uptake of 18FDG was observed rapidly at 2, 4, and 24 hours 
after administration of an efficacious dose of 60 mg/kg of OSI-906 in NCI-H292 tumor 
bearing animals. In comparison, the insensitive NCI-H441 xenografts  demonstrated no 
change in uptake of the radiotracer at the same time points and same dosage. Analysis 
of target inhibition of pAKT, pS6, pERK 1/2, pIGF-1R and pIR from NCI-H292 tumor 
lysates was performed by Western blot and RTK array analysis. The results showed 
strong target inhibition of these markers  at 4 hours post administration of a single 60 
mg/kg dose of OSI-906, further corroborating the link of metabolic activity of tumors with 
IGF-1R and IR signaling pathways. Specific target inhibition of pIGF-1R and IR by RTK 
array analysis resulted in significant (p <0.05) reduction of these phospho-targets 
(>80%) at 2 and 4 hours post administration of the agent, and correlated to reduced 
uptake of 18FDG. Blood glucose levels were elevated from a baseline, fasted level 
following 2 and 4 hours of 60mg/kg OSI-906 treatment, however, these levels  did not 
reach statistical significance (p>0.5). As expected, similarly evaluated vehicle treated 
mice did not exhibit elevated glucose levels  when evaluated at 2 hrs  and 4 hrs (Fig. 7A). 
Importantly, 18FDG uptake in NCI-H441 tumors, which are insensitive to OSI-906, was 
similar in both OSI-906-treated and vehicle-treated tumors. The fact that post-treatment 
18FDG uptake in these mice was not decreased when compared to baseline imaging 
suggests that the somewhat elevated circulating glucose levels had no detectable 
impact on 18FDG uptake in this  study. As  further evidence, no change in 18FDG uptake 
was seen in skeletal muscle following OSI-906 (Fig. 7B), and only a slight increase in 
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liver 18FDG uptake was seen at 2 and 4 hours before returning to baseline at 24 hours 
(Fig. 7C). 
  The present findings support a strong link of rapidly altered metabolic activity in 
both cultured cells and in vivo tumors induced by target inhibition of the IGF-1R and IR 
signaling pathways. Though there is still much to be learned how cellular metabolism in 
proliferating cells is regulated, there is  an ever increasing body of information supporting 
increased communication between signaling pathways and metabolic control of the cell. 
Thus, 18FDG-PET should serve as a rapid, non-invasive biomarker of pharmacodynamic 
effects of OSI-906 in patients  treated with this  dual IGF-1R/IR kinase inhibitor. This 
method may be most beneficial in early clinical development where accurate 
assessment of PD effects is often times limited by the lack of readily accessible tumor 
samples. As such 18FDG-PET may be a useful clinical tool in identifying active doses 
and patients potentially sensitive to this novel antitumor agent and perhaps other 
compounds of this target class. Currently, 18FDG-PET imaging is being employed in 
several clinical trials as a biomarker for early efficacy of OSI-906.  
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CHAPTER III
DISCUSSION
III.1 Future Work
 While 18FDG-PET was well suited for use in these studies, the complex 
underlying biology of glucose metabolism may dictate the predilection of other types of 
probes for certain tumors and treatment types. As such, many new molecular imaging 
probes are currently being developed. Contemporary molecular imaging research 
emphasizes the use of new probes to measure biological targets other than glucose 
metabolism. One such probe is 3’-deoxy-3’[18F]-fluorothymidine (18FLT), a marker of 
proliferation (33). 18FLT is a thymidine analog that when phosphorylated by the cytosolic 
enzyme Thymidine Kinase 1 (TK1) is trapped inside the cell. We have previously shown 
that 18FLT may be a biomarker of response to HER2 targeted therapy in breast cancer 
while 18FDG is not (19). However, another study shows that 18FLT is  not a biomarker of 
response in epidermal growth factor receptor targeted therapy in colorectal cancer (17). 
These seemingly disparate results  have led us to look deeper into the cellular 
mechanisms of TK1 regulation and will be a large component of our future research. 
Understanding under what circumstances 18FDG or 18FLT would be better suited in 
imaging treatment response will be of great clinical importance. In addition to 18FLT, we 
are developing novel imaging probes for translator protein (TSPO), a trans-
mitochondrial membrane protein involved in a number of cellular processes including 
cholesterol metabolism, steroidogenesis, and apoptosis. Additionally, TSPO expression 
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levels  have been shown to be correlated to tumor grade (34, 35) and patient outcomes 
across a number of cancer types (36-38). A number of probes have been developed for 
neuroimaging such as PBR06 (39) and DPA-714 (40). However, until recently these 
probes have not been evaluated in the context of cancer. In fact, we were the first to 
show that PBR06 is a promising probe for imaging rat models of glioma (41), and are 
currently moving forward to preliminary clinical use with these agents. However, all 
TSPO targeted imaging probes  currently in use were not developed for cancer imaging, 
and the development of a new generation of probes specifically targeting cancer may 
show significantly better performance than current agents. We have embarked on an 
ambitious probe discovery project involving the synthesis of hundreds of novel small 
molecules based upon the PBR06 and DPA-714 parent scaffolds (42). These new 
ligands  are screened by a number of functional assays including radioligand 
displacement, generation of reactive oxygen species, and steroidogenesis. After 
screening for desirable properties, the novel ligands are labelled with 18F for PET 
imaging in small animals, biological validation and ultimately use in humans. With the 
development and validation of 18FLT and TSPO targeted imaging probes we aim to 
increase the molecular imaging tools available for clinicians beyond 18FDG to help 
diagnose disease and direct therapy.
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